Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is expected to report second quarter earnings results, after market close, on Monday 10th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.08 per share.
Looking ahead, the full year income are expected at $ 0.37 per share on the revenues of $ 126.64 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 135.00 million ~ $ 155.00 million
Click Here For More Historical Outlooks Of Catalyst Pharmaceuticals, Inc.
Previous Quarter Performance
Catalyst Pharmaceuticals, Inc. disclosed income for the first quarter of $ 0.10 per share, from the revenue of $ 29.14 million. The consensus estimates are income of $ 0.09 per share from $ 31.46 million in revenue. The bottom line results beat street analysts by $ 0.01 or 11.11 percent, at the same time, top line results fell short of analysts by $ 2.32 million or 7.37 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Catalyst Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of CPRX was $ 4.05, representing a 58.82 % increase from the 52 week low of $ 2.55 and a 47.2 % decrease over the 52 week high of $ 7.67.
The company has a market capital of $ 418.88 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CPRX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3.
